Introduction
stirred at room temperature for 6 h. Sodium hydroxide 6 M (40 ml) was then added and vigorous stirring was continued for another 4 h. The aqueous phase was separated and acidified with concentrated hydrogen chloride. The solid was collected by filtration and recrystallized from ethyl acetate:hexane to give 5 g (53%) of thienothia-diazine 1 as a white crystalline solid: M.p. 230ºC; 1 H-NMR (200 MHz, DMSO-d 6 ) δ 7.33 (s, 1H, H-7), 7.41-8.00 (m, 5H, Ph) . 13 C-NMR (50 MHz, DMSO-d 6 ): δ 113.02 (C-4a), 118.72 (C-5), 125.35 (Cp), 127.62, 129.92 (Co and Cm), , 133.50 (Ci), 157.03 (C-7a), 162.08 (C-4). Anal. Calcd. for C 11 H 8 N 2 O 3 S 2 : C, 47.13; H, 2.88; N, 9.99; S, 22.87. Found: C, 47.12; H, 2.91; N, 10.01; S, [1,2,6]thiadiazin-4(3H)-one 2,2-dioxide (12) To a solution of thienothiadiazine 1 (3.00 g, 0.012 mol) in aqueous sodium bicarbonate pH 8 (100 ml), benzyl bromide (2.07 g, 0.012 mol) was added. The reaction mixture was stirred at room temperature for 15 min and afterwards extracted with ethyl acetate (3×100 ml). The organic phase was dried over sodium sulphate and the solvent evaporated under reduced pressure. The residue was chromatographed on a silica gel column using dichloromethane:methanol 100:7 as eluent. Compound 12 (1.25 g, 30 %) was obtained as a white crystalline solid: M.p. 203 o C; 1 H-NMR (200 MHz, DMSO-d 6 ) δ 4.86 (s, 2H, CH 2 Ph), 7. 11H, . 13 C-NMR (50 MHz, DMSO-d 6 ) δ 51.27 (CH 2 Ph), 118.88 (C-4a), 121.44 (C-5), 124.76, 127.26, 127.49, 128.01, 128.16, 129.09, 133.87, 136.59 (Car) , 129.50 (C-6), 152.46 (C-7a), 163.89 (C-4). Anal. calcd. for C 18 H 14 N 2 O 3 S 2 : C, 58.36; H, 3.81; N, 7.56; S, 17.31. Found: C, 58.31; H, 3.92; N, 7.76; S, [1, 2, 6] thiadiazin-4(3H)-one 2,2-dioxide (13)
Benzyl bromide (0.12 ml, 0.001 mol) was added to a solution of thienothiadiazine 2 (Rozas, 1987) (0.28 g, 0.001 mol) in a sodium bicarbonate aqueous solution (10 ml). The reaction mixture was stirred at room temperature for 12 h. The aqueous phase was extracted with ethyl acetate (5×10 ml). The organic phase was dried over sodium sulphate and the solvent evaporated under reduced pressure. The residue was recrystallized from ethyl acetate to give compound 13 (0.32 g, 95%) as a white crystalline solid: M.p. 235-236 o C; 1 H-NMR (200 MHz, DMSO-d 6 ) δ 5.08 (s, 2H, CH 2 Ph), 7. 10H, Ph), 7.91 (s, 1H, . 13 C-NMR (50 MHz, DMSO-d 6 ): δ 48.82 (CH 2 Ph), 110.81 (C-4a), 113.95 (C-7), 125.70, 127.35, 128.41, 129.70, 129.27, 132.68, 137.35 (Car) , 147.07 (C-7a), 147.96 (C-6), 162.74 (C-4). Anal. calcd. for C 18 H 14 N 2 O 3 S 2 : C, 58.36; H, 3.81; N, 7.56; S, 17.31. Found: C, 58.34; H, 3.85; N, 7.84; S, 17.28 .
General method for the synthesis of thieno thiadiazine acyclonucleosides
To a solution in CH 2 Cl 2 (25 ml) of the silyl derivative of the thienothiadiazine dioxide (1 mmol) prepared by refluxing the base in HMDS (3 ml) under nitrogen using suitable catalyst and cosolvents, the dissolved acyclic moiety precursor in CH 2 Cl 2 (25 ml) was added. The mixture was cooled and BF 3 .Et 2 O (1.40 mmol) was added under vigorous stirring and exclusion of moisture. The resulting mixture was stirred at room temperature for 1-3 h and was then shaken with saturated sodium hydrogencarbonate solution (50 ml). The organic phase was separated, dried over sodium sulphate and evaporated under reduced pressure. The residue was chromatographed on a silica gel column, using as eluent, mixtures of solvents in the proportions indicated for each case.
1-[(2-Acetoxyethoxy)methyl]-6-phenylthieno[2,3-c][1,2,6]thiadiazin-4(3H)-one 2,2dioxide (4) and 1,3-di[(2-acetoxyethoxy)methyl]-6-phenyl-thieno[2,3-c][1,2,6] thiadiazin-4(3H)-one 2,2-dioxide (5) Reagents: (i) thienothiadiazine dioxide 1 (0.19 g, 0.7 mmol), HMDS (3 ml), SO 4 (NH 4 ) 2 (catalytic amounts), anhydrous pyridine (1 ml); (ii) acetoxyethyl acetoxymethyl ether (Rosowsky et al., 1981) , 52.49; H, 5.03; N, 5.83; S, 13.35 . , 52.31; H, 5.25; N, 6.10; S, 13.01. Purification and isolation: second fraction, CH 2 Cl 2 :MeOH (100:7), yield 0.10 g (50 %) of compound 4 as a foam. 1 H-NMR (200 MHz, DMSO-d 6 ) δ 1.96 (s, 3H, CH 3 CO), 3.66 (m, 2H, OCH 2 CH 2 OCO), 3.98 (m, 2H, OCH 2 CH 2 OCO), 5.11 (s, 2H, OCH 2 N), 7.12-7.45 (m, 5H, Ph), 7.30 (s, 1H, H-5); 13 C-NMR (50 MHz, DMSO-d 6 ): δ 20.61 (CH 3 CO), 63.00 (OCH 2 CH 2 OCO), 66.01 (OCH 2 CH 2 OCO), 69.92 (OCH 2 N), 110.84 (C-4a), 119.26 (C-5), 124.09 (Cp), 126.13 (Co), 128.84 (Cm), 129.06 (C-6), 139.25 (Ci), 160.67 (C-7a), 166.11 (C-4), 170.27 (CH 3 CO). Anal. calcd. for C 16 H 16 N 2 O 5 S 2 C, 50.52; H, 4.24; N, 7.36; S, 16.85. Found: C, 50.84; H, 4.40; N, 7.15; S, 16.51 .
Reagents: (i) thienothiadiazine dioxide 2 (Rozas, 1987) (0.34 g, 2 mmol), HMDS (6 ml), SO 4 (NH 4 ) 2 (catalytic amounts); (ii) acetoxyethyl acetoxymethyl ether (Rosowsky et al., 1981) , 37.47; H, 3.97; N, 9.20; S, 21.07. Found: C, 37.35; H, 3.98; N, 8.82; S, 20.89. 3-[(2-Acetoxyethoxy)methyl]-6-phenylthieno[3,2-c][1,2,6]thiadiazin-4(1H)-one 2,2-Dioxide (9) Reagents: (i) thienothiadiazine dioxide 3 (Rozas, 1987) (0.28 g, 1 mmol), HMDS (3 ml), SO 4 (NH 4 ) 2 (catalytic amounts), pyridine (2 ml); (ii) acetoxyethyl acetoxymethyl ether (Rosowsky et al., 1981) , 4.24; N, 7.36; S, 16.85. Found: C, 50.72; H, 4.33; N, 7.21; S, 16.50 . (14) Reagents: (i) Thienothiadiazine dioxide 12 (0.26 g, 0.7 mmol), HMDS (3 ml), SO 4 (NH 4 ) 2 (catalytic amounts), anhydrous pyridine (1 ml); (ii) acetoxyethyl acetoxymethyl ether (Rosowsky et al., 1981) 125.49, 128.44, 128.74, 128.78, 128.79, 129.25, 133.41, 138.29 (Car) , 131.63 (C-6), 149.26 (C-7a), 157.59 (C-4), 170.20 (CH 3 CO). Anal. calcd. for C 23 H 22 N 2 O 5 S 2 : C, 58.71; H, 4.71; N, 5.95; S, 13.63. Found: C, 58.84; H, 4.63; N, 5.64; S, 13.54 . (16) Reagents: (i) thienothiadiazine dioxide 13 (0.67 g, 2 mmol), HMDS (6 ml), SO 4 (NH 4 ) 2 (catalytic amounts), anhydrous pyridine (1 ml); (ii) acetoxyethyl acetoxymethyl ether (Rosowsky et al., 1981) (0.35 g, 2 mmol), BF 3 .Et 2 O (3 mmol).
Purification: CH 2 Cl 2 , yield 0.50 g (50%) of compound 16 as a syrup. 1 H-NMR (200 MHz, DMSO-d 6 ) δ 1.98 (s, 3H, CH 3 CO), 3.69 (m, 2H, OCH 2 CH 2 OCO), 4.10 (m, 2H, OCH 2 CH 2 OCO), 5.20 (s, 2H, CH 2 Ph), 5.23 (s, 2H, OCH 2 N), 7.30 (m, 5H, Ph), 7.49-7.81 (m, 5H, Ph), 7.92 (s, 1H, H-7); 13 C-NMR (50 MHz, DMSO-d 6 ) δ 20.67 (CH 3 CO), 53.87 (CH 2 Ph), 62.72 (OCH 2 CH 2 OCO), 67.07 (OCH 2 CH 2 OCO), 72.59 (OCH 2 N), 114.36 (C-4a), 117.34 (C-7), 126.20, 128.40, 128.67, 128.07, 129.53, 130.41, 131.65, 134.47 (Car) , 144.75 (C-7a), 152.25 (C-6), 157.37 (C-4), 170.36 (CH 3 CO). Anal. calcd. for C 23 H 22 N 2 O 5 S 2 : C, 58.71; H, 4.71; N, 5.95; S, 13.63. Found: C, 58.67; H, 4.55; N, 5.99; S, 13.98 .
Reagents: (i) thienothiadiazine dioxide 12 (0.21 g, 0.6 mmol), HMDS (3 ml), SO 4 (NH 4 ) 2 (catalytic amounts); (ii) benzyloxymethyl ether (Renault et al., 1994) 126.30, 128.39, 128.51, 129.07, 129.47, 129.65, 133.41, 137.64, 139.53 (Car) , 129.18 (C-5), 149.86 (C-7a), 159.14 (C-4). Anal. calcd. for C 26 H 22 N 2 O 5 S 2 : C, 61.64; H, 4.38; N, 5.53; S, 12.66. Found: C, 61.85; H, 4.38; N, 5.20; S, 12.61 .
A solution of acyclonucleoside 16 (0.20 g, 0.4 mmol) in MeOH (30 ml) was hydrogenated with 70.3 kg/m -2 (10 psi) of hydrogen in the presence of 20% palladium/charcoal catalyst (0.020 g) at room temperature. After 2 h the catalyst was filtered off and the solvent removed in vacuo. The residue was dissolved in AcOEt and washed with water. The organic phase was dried over sodium sulphate and the solvent eliminated under reduced pressure yielding 0.14 g (89%) of derivative 18. 1 , 4.24; N, 7.36; S, 16.85. Found: C, 50.51; H, 4.10; N, 7.21; S, 16.98 .
General procedure for the enzymatic cleavage of acetyl group A solution of the acylated acyclonucleoside (2 mmol) in t-BuOH:buffer pH 7 (90:10) was incubated with 10 mg/ml of CAL at 45 o C and 250 r.p.m. in an orbital shaker for 4 h. When all the starting material had disappeared, the enzyme was removed by filtration and washed with methanol. The filtrate was evaporated in vacuo and the deprotected compound was obtained as a syrup. The compounds obtained were as follows. , 46.65; H, 5.59; N, 7.77; S, 17.79. Found: C, 46.45; H, 5.71; N, 7.57; S, 17. , 4.70; N, 6.54; S, 14.97. Found: C, 47.45; H, 4.71; N, 6.57; S, 14. 72. 128.46, 128.49, 128.75, 128.80, 129.27, 133.45, 139 .25 (Car), 149.20 (C-7a), 157.61 (C-4). Anal. calcd. for C 21 H 20 N 2 O 5 S 2 : C, 56.74; H, 4.53; N, 6.38; S, 14.42. Found: C, 56.50; H, 4.19 ; N, 6.21; S, 14.50.
3-Benzyl-1-[(2-hydroxyethoxy)methyl]-6-phenylthieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2dioxide (17) Yield 0.08 g (90%). 1 H-NMR (200 MHz, DMSO-d 6 ) δ 3.52 (m, 4H, OCH 2 CH 2 OH), 5.20 (s, 2H, CH 2 Ph), 5.23 (s, 2H, OCH 2 N), 7.29 (m, 5H, Ph), 7.41-7.79 (m, 5H, Ph), 7.89 (s, 1H, H-7); 13 C-NMR (50 MHz, DMSO-d 6 ) δ 53.89 (CH 2 Ph), 59.89 (OCH 2 CH 2 OH), 71.19 (OCH 2 CH 2 OH), 73.00 (OCH 2 N), 116.44 (C-4a), 117.31 (C-7), 152.19 (C-6), 126.22, 128.09, 128.40, 128.71, 129.54, 130.39, 131.72, 134.47 
Materials and Methods: Virology
The compounds were evaluated for antiviral activity following established procedures (De Clercq, 1994) .
Cells and viruses
Human embryonic lung (HEL) fibroblast cells were propagated in Eagle's MEM supplemented with 10% inactivated fetal calf serum, 1% L-glutamine and 0.3% sodium bicarbonate. Two reference strains of VZV expressing viral thymidine kinase (TK + ) (YS and Oka) and two reference strains of VZV lacking the viral thymidine kinase (TK -) (07-1 and YS-R) were included in the study. VZV stocks were prepared in HEL cells as cell-associated viruses. When 70% cytopathic effect was obtained, the cells were trypsinized, resuspended in medium containing 10% DMSO and stored in aliquots at -80 o C. The Davis and AD-169 strains were used as HCMV stocks. HCMV stocks consisted of cell-free virus obtained from the supernatant of infected cell cultures that had been clarified by low speed centrifugation. The virus stocks were stored at -80 o C.
Antiviral assays
Confluent HEL cells grown in 96-well microtitre plates were infected with the different virus strains at 20 (VZV) and 100 (HCMV) plaque-forming units (p.f.u.) . After a 2h incubation period, residual virus was removed and the infected cells were further incubated with MEM supplemented with 2% inactivated FCS, 1% l-glutamine and 0.3% sodium bicarbonate containing serial dilutions of the test compounds (in duplicate). After 5 and 7 days of incubation for VZV and HCMV, respectively at 37 o C in 5% CO 2 atmosphere, the cells were fixed with ethanol and stained with 2.5% Giemsa solution. Virus plaque formation (VZV virus input: 20 p.f.u.) or viral cytophatic effect (HCMV virus input: 100 p.f.u.) was monitored microscopically. The antiviral activity is expressed as IC 50 which represents the compound concentration required to reduce virus plaque formation or cytopathicity by 50%. IC 50 , values were estimated from graphic plots of the number of plaques (percentage of control) or percentage of cytopathicity as a function of the concentration of the test compounds.
Cytotoxicity assays
Cytotoxicity measurements were based on the inhibition of HEL cell growth. HEL fibroblasts were seeded at a rate of 5×10 3 cells/well microtitre plates and allowed to proliferate for 24 h. Different concentrations of the test compounds were then added (in duplicate), and after 3 days of incubation at 37 o C in 5% CO 2 atmosphere the cell number was determined with a coulter counter. Cytotoxicity is expressed as CC 50 , which represents the compound concentration required to reduce cell growth by 50%. As a second parameter of cytotoxicity, the minimum toxic concentration (MTC) of the compounds required to cause a microscopically detectable alteration in normal cell morphology was also evaluated.
Antiretroviral evaluation
HIV-1 (HTLV-IIIb) was kindly provided by Dr RC Gallo (National Institutes of Health, Betheseda, Md., USA). Virus stocks were prepared from the supernatants of HIV-1-infected MT-4 cells. HIV-2 (strain ROD) was provided by Dr L Montagnier (Pasteur Institute, Paris, France) and virus stocks were prepared from the supernatants of HIV-2-infected MT-4 cells. CEM cells were obtained from the ATCC (Rockville, Md., USA). CEM cells were infected as follows: 4×10 5 cells/ml were infected with HIV-1 or HIV-2 at ~100 CCID 50 (50% cell culture infective dose) per ml of cell suspension. Then 100 µl of the infected cell suspension was transferred to 96-well microtitre plate wells and mixed with 100 µl of the appropiate dilutions of the test compounds. After 4 days the HIV-infected cell cultures were examined microscopically for giant cell formation.
Results and Discussion
Chemistry Thienothiadiazine dioxides 1-3 were prepared following a synthetic strategy that involves the cyclocondensation of functionalized thiophenes with sulphamoyl choride as the key step (Figure 2) .
The synthesis of the acyclonucleosides was achieved according to the silylation method (Vörbruggen et al., 1974) . Thus, thienothiadiazines 1-3 were first silylated using hexamethyldisilazane (HMDS) and ammonium sulphate as catalyst under nitrogen atmosphere. Reaction of these silyl derivatives with acetoxyethoxy acetoxymethyl ether (Rosowsky et al., 1981) in dichloromethane and boron trifluoride as catalyst afforded the reaction products in Figure 3 . Deprotection of the isolated acyclonucleosides was achieved quantitatively using a lipase-mediated deacylation procedure with CAL in a hydrolytic medium (t-BuOH/buffer pH 7). This methodology has previously been described by our group (Martinez et al., 1995) and has been successfully applied to the regioselective deacylation of thiadiazine dioxide diacyclonucleosides (Esteban et al., 1994; Conde et al., 1998) .
A protection-deprotection strategy was employed for obtaining the thienothiadiazine acyclonucleoside isomers. N-benzylthienothiadiazines 12 and 13 were obtained by reaction of 1 and 3 with benzyl chloride in aqueous bicarbonate, respectively (Figure 4 ). Silylation of 12 and 13 with HMDS and catalytic amounts of ammonium sulphate, followed by reaction with the acyclic moiety in dichloromethane and boron trifluoride etherate as catalyst, yielded, after chromatographic purification, the N-benzyl protected acyclonucleosides 14 and 16. The cleavage of the N-benzyl was performed initially by catalytic hydrogenolysis using Pd/C as catalyst. Under these conditions only debenzylation of compound 16 was accomplished. Debenzylation of acyclonucleoside 14 was unsuccessful when employing conditions such as H 2 /Ni Raney, Na/NH 3 , and Fe/HCl. The CAL mediated deacylation procedure was used to obtain the hydroxyethoxymethyl derivatives 15, 17 and 19 in quantitative yields.
Introduction of lipophilic acyclic moieties such as the benzyloxymethyl group (Renault et al., 1994) was achieved on N-benzylthienothiadiazine 12, following the experimental conditions previously described ( Figure 5) . The structures of all new compounds were elucidated according to analytical and spectroscopic data. The site of glycosylation of thieno[3,2-c][1,2,6]thiadiazines (2 and 3) was determined on the basis of N.O.e. experiments, while for thieno[2,3-c][1,2,6]thiadiazine 1, the 13 C NMR data of 1-and 2-dimensional experiments were necessary for this determination. Unequivocal assignment of all chemical shifts ( 1 H and 13 C) was done using 2-dimensional experiments such as HMQC (Bax et al., 1986) for one-bond correlation and HMBC (Bax et al., 1988) for long-distance couplings.
Once the unequivocal structure assignment had been performed, the different reactivity of the thienothiadiazine 3 was evident. The nitrogen atom situated between the carbonyl and the SO 2 moieties is the first reactive point in both glycosylation and benzylation conditions. The acid-base properties of thienothiadiazines could play an important role in their experimental behaviour.
Although nitrogen-containing organic compounds are best known for their basic properties, a number of such compounds also exhibit acidic properties, as in the case of 1,2,6-thiadiazin-4-ones (Arán et al., 1988) . However, if two amide groups coexist in the molecule one may wonder which one is the preferred site for deprotonation.
For the experimental determination of the pKa values of thienothiadiazines 2, 3 and 12, UV spectroscopy was used (Albert et al., 1971) . The results depicted in Figure 6 show the acidic character of these nitrogen-containing heterocycles. By comparison of the values with those of the compounds in which one position is blocked by the substituent, it has been possible to assign the ionization sequences. The pKa value of Ni Pr derivative depicted in Figure 6 has been previously measured (Rozas, 1987) . As can be seen, the deprotonation pattern of 2 and 3 is in agreement with experimental observed results, and could explain the different reactivity found in such heterocycles. Moreover, partial atomic charges of dianion derived from 3 were determined by fitting point charges to electrostatic potential at HF/6-31*G level via ab initio molecular orbital calculations using Gaussian 94 (Frisch et al., 1995) . These results showed a preference for nucleophilic substitution at N3 (Figure 6 ), in agreement with the experimental observation.
Antiviral evaluation results
All the synthesized TTD acyclonucleosides were evaluated for their antiviral activity in a wide variety of assay systems (De Clercq, 1994) : herpes simplex virus type 1 (strains KOS, F McIntyre), herpes simplex virus type 2 (strains G, 196, Lyons), thymidine kinase-deficient (TK -) herpes simplex virus type 1 (strains B2006, VMW1837), vaccinia virus and vesicular stomatitis virus in E 6 SM cells; vesicular stomatitis virus, poliovirus type 1 and Coxsackie B4 virus in In addition, antiviral activity against HCMV, strains AD-169 and Davis, and VZV, strains OKA, YS, 07/1 and YS/R, was determined by plaque reduction (VZV) (Andrei et al., 1995) or CPE reduction (HCMV) (Snoeck et al., 1991) assays in confluent HEL fibroblasts. Cytotoxicity measurements were based on the inhibition of cell growth. Antiviral activity was noted at concentrations lower than 50 µg/ml and these results are presented in vity against VZV. Compound 12 must have interfered with the morphology of the cells so that its activity against VZV could not be assessed at concentrations greater than 5 µg/ml.
From these results, it is clear that the 2,1,3-benzothiadiazine dioxide moiety must play an important role in the activity against HCMV, because the replacement by different thienothiadiazine heterocycles led to loss of the antiviral activity. Moreover, the thienothiadiazine dioxide acyclonucleosides reported here resulted in cytotoxicity. Only minor antiviral activity is observed when the benzyl group is present as the substituent, which is in agreement with recently described anti-HCMV data (Pinto et al., 1996; Martinez et al., 1999b) . It is likely that benzyl groups are involved in the receptor binding of these new agents at its as yet un-identified target site. Additionally, the fact that compounds are equally active against TKstrains of VZV, and the fact that the hydroxy group is not required for activity, points to a mechanism of action different to that of DNA polymerase inhibition. So although the chemical structure resembles that of the acyclonucleosides, this kind of compound acts as a non-nucleosidic drug. Modifications in the benzyl group and/or in the acyclonucleoside (side lateral chain) fragment of the molecules are in progress in order to improve the anti-HCMV activity previously reported.
